Molecular Cancer Therapeutics CTRC-AACR San Antonio Breast Cancer Symposium Targeting the PI3-Kinase Pathway in Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shabbits, J. A.
Right arrow Articles by Mayer, L. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shabbits, J. A.
Right arrow Articles by Mayer, L. D.
Vol. 1, 205-213, January 2002     Molecular Cancer Therapeutics
© 2002 American Association for Cancer Research

P-Glycoprotein Modulates Ceramide-mediated Sensitivity of Human Breast Cancer Cells to Tubulin-binding Anticancer Drugs1

Jennifer A. Shabbits and Lawrence D. Mayer2

Department of Advanced Therapeutics, British Columbia Cancer Research Centre, Vancouver, British Columbia, V5Z 1L3 Canada, and Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, V6T 1Z3 Canada

Alterations in metabolism of ceramide (Cer) to the noncytotoxic metabolite glucosylceramide have been implicated in the multidrug resistance (MDR) phenomenon. This observation has been made with tumor cells that also overexpress P-glycoprotein (Pgp), raising the possibility that Pgp plays a role in regulating Cer metabolism. We investigated the effect of the glucosylceramide synthase inhibitor 1-phenyl-2-decanoylamino-3-morpholino-1-propanol (PDMP) on the chemosensitivity of two wild-type and multidrug-resistant human breast tumor cell lines. Subtoxic concentrations of PDMP sensitized drug-selected MCF7/AdrR and Pgp-overexpressing MDA435/LCC6MDR1 (MDR1 gene-transfected) cell lines to Taxol and vincristine but did not alter the chemosensitivity of the wild-type cells. Evaluation of Taxol uptake indicated that the effect of PDMP was not due to membrane permeability alterations because anticancer drug accumulation was unaffected by PDMP. Whereas both multidrug-resistant cell lines overexpress Pgp, only the MCF7/AdrR cell line overexpresses the glucosylceramide synthase enzyme. This difference enabled us to distinguish between sensitization effects associated with Cer metabolism versus Pgp-mediated transport. Interestingly, when Pgp function was blocked, the PDMP effect was reduced 3-fold in MCF7/AdrR cells and was no longer observed in the MDA435/LCC6MDR1 cells. These observations imply that Cer metabolism and apoptosis effects are regulated not only by enzymes that convert Cer to nontoxic metabolites but also by Pgp-mediated transport. Given the intracellular distribution patterns of Pgp, we propose that this effect is related to glucosylceramide translocation across the Golgi bilayer. We have applied this model to the situation of Cer metabolism-based chemosensitization and demonstrate that MDR modulation strategies aimed primarily at altering drug transport mechanisms can influence other MDR mechanisms such as glycosphingolipid metabolism. This work highlights the relationship between drug transport and Cer metabolism in the context of chemosensitization and cautions against making oversimplified assumptions that these mechanisms act independently.




This article has been cited by other articles:


Home page
Mol Cancer ResHome page
K. Arai, Y. Matsumoto, Y. Nagashima, and K. Yagasaki
Regulation of Class II {beta}-Tubulin Expression by Tumor Suppressor p53 Protein in Mouse Melanoma Cells in Response to Vinca Alkaloid
Mol. Cancer Res., April 1, 2006; 4(4): 247 - 255.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
V. Gouaze, Y.-Y. Liu, C. S. Prickett, J. Y. Yu, A. E. Giuliano, and M. C. Cabot
Glucosylceramide Synthase Blockade Down-Regulates P-Glycoprotein and Resensitizes Multidrug-Resistant Breast Cancer Cells to Anticancer Drugs
Cancer Res., May 1, 2005; 65(9): 3861 - 3867.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
E. Norris-Cervetto, R. Callaghan, F. M. Platt, R. A. Dwek, and T. D. Butters
Inhibition of Glucosylceramide Synthase Does Not Reverse Drug Resistance in Cancer Cells
J. Biol. Chem., September 24, 2004; 279(39): 40412 - 40418.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
V. Gouaze, J. Y. Yu, R. J. Bleicher, T.-Y. Han, Y.-Y. Liu, H. Wang, M. M. Gottesman, A. Bitterman, A. E. Giuliano, and M. C. Cabot
Overexpression of glucosylceramide synthase and P-glycoprotein in cancer cells selected for resistance to natural product chemotherapy
Mol. Cancer Ther., May 1, 2004; 3(5): 633 - 640.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. F. De Rosa, D. Sillence, C. Ackerley, and C. Lingwood
Role of Multiple Drug Resistance Protein 1 in Neutral but Not Acidic Glycosphingolipid Biosynthesis
J. Biol. Chem., February 27, 2004; 279(9): 7867 - 7876.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
J. A. Shabbits, Y. Hu, and L. D. Mayer
Tumor Chemosensitization Strategies Based on Apoptosis Manipulations
Mol. Cancer Ther., August 1, 2003; 2(8): 805 - 813.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
Copyright © 2002 by the American Association for Cancer Research.